Table 3 Univariate analysis of possible risk factors for type 1 gastric NET recurrence
From: Management of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center study
Factor | n/N | Median RFS (months) | P | HR (95% CI)* |
|---|---|---|---|---|
Sex | ||||
Male | 31/65 | 22 | 0.123 | 1 |
Female | 39/105 | 46 | 0.70 (0.43–1.11) | |
Maximum diameter of tumor (cm) | ||||
< 0.5 | 13/45 | > 122 | 0.027 | 1 |
0.5–0.9 | 30/66 | 27 | 1.71 (0.89–3.28) | |
1.0–1.9 | 14/27 | 25 | 2.63 (1.23–5.60) | |
≥ 2.0 | 5/8 | 18 | 3.38 (1.20–9.54) | |
Endoscopic treatment | ||||
No | 6/24 | > 122 | 0.146 | 1 |
Yes | 64/146 | 34 | 1.83 (0.79–4.23) | |
TCM treatment | ||||
No | 18/42 | 18 | 0.163 | 1 |
Yes | 52/128 | 46 | 0.69 (0.4–1.18) |